Subgroup analysis of PEARLS/KEYNOTE-091: PD-L1 expression and outcomes of pembrolizumab - YouTube
Pembrolizumab in Early-Stage Non-Small Cell Lung Cancer After Complete Resection
Adjuvant Pembrolizumab Approval Adds to Prevention of Recurrent NSCLC
Treatment benefits and outcome determinants in (neo)adjuvant trials - memoinOncology
Stephen V Liu, MD on Twitter: "#ASCO22 Discussion of PEARLS (KEYNOTE-091, @ETOP_eu 8-15), a phase III study of adjuvant pembrolizumab in resected NSCLC. The study did meet its primary endpoint (DFS HR
KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement In Disease-Free Survival Versus Placebo As Adjuvant Treatment For Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless Of PD-L1 Expression 2023 - EORTC
FDA OKs Adjuvant Pembrolizumab for NSCLC | MedPage Today
Aakash Desai, MD, MPH on Twitter: "@LuisPaz_Ares discussed data from #PEARLS study #Pembrolizumab for early stage #NSCLC #LCSM with dual primary endpoint of DFS in all comers/PDL1>50%, showing significant DFS improvement HR:0.76
Stephen V Liu, MD on Twitter: "The #ESMOVirtualPlenary presented by Dr. @LuisPaz_Ares presents results from EORTC-1416-LCG / ETOP 8-15 / PEARLS / KEYNOTE-091: adjuvant pembrolizumab versus placebo for resected early stage #NSCLC. @
癌免疫療法による周術期治療で呼吸器外科の治療体系は変わる(2ページ目)：日経メディカル
Frühes nichtkleinzelliges Bronchialkarzinom: Pembrolizumab adjuvant nach Resektion verlängert das krankheitsfreie Überleben
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial - The Lancet Oncology
Adjuvant pembrolizumab extends DFS in resected early-stage non-small cell lung cancer
Pembrolizumab improves DFS in completely resected stage IB–IIIA NSCLC | Latest news for Doctors, Nurses and Pharmacists | Oncology
Stephen V Liu, MD on Twitter: "#ASCO22 Discussion of PEARLS (KEYNOTE-091, @ETOP_eu 8-15), a phase III study of adjuvant pembrolizumab in resected NSCLC. The study did meet its primary endpoint (DFS HR
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial - The Lancet Oncology
Adjuvant Immunotherapy Approved for Lung Cancer - NCI
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial - The Lancet Oncology
Pembrolizumab in Metastatic Non–Small-Cell Lung Cancer | NEJM Resident 360
ES/ONCO/1118/0300. - ppt download
Adjuvant Immunotherapy in Non–Small Cell Lung Cancer: Who Benefits?
Frühes nichtkleinzelliges Bronchialkarzinom: Pembrolizumab adjuvant nach Resektion verlängert das krankheitsfreie Überleben
Is Adjuvant Pembrolizumab Clinically Valuable?
